OTEF Earns Candid’s Platinum Seal Of Transparency for 2023

Oct 8, 2023

The Platinum Seal is the highest level of recognition offered by Candid (formerly known as GuideStar) and is awarded to organizations that meet the highest standards of transparency and accountability.

“We are honored to receive the Candid Platinum Seal of Transparency,” said Joan Koerber-Walker, chairman of the Opportunity Through Entrepreneurship Foundation (OTEF). “This recognition illustrates OTEF’s  commitment to transparency and accountability in our programs and operations. By sharing our data, metrics, and strategic priorities with the public, we can build trust and confidence in our organization and our work.”

The Opportunity Through Entrepreneurship Foundation (OTEF) has supported Arizona entrepreneurs and at-risk populations since 2005. Beginning in 2019, our AZAdvances program has focused on Arizona’s growing entrepreneurial base in the area of health innovation.

 Arizona needs to increase its STEM workforce and provide higher levels of entrepreneurial support to our emerging life science companies if our community is to achieve it’s goal of doubling impact by 2033. 

OTEF is proud to be part of a community of Organizations that is working to address this need.

About the Candid Platinum Seal

To earn the Candid Platinum Seal, non-profit organizations must meet a rigorous set of criteria, including:

  • Providing complete and accurate information about their mission, programs, finances, and governance on Candid

  • Sharing their strategic priorities and information about their impacts

  • Being open to feedback and engagement from the public

In 2023, fewer than one percent of U.S.-based non-profit organizations have been recognized with the Platinum Seal to date.

For more information about the Candid Platinum Seal, please visit www.candid.org.

Related Posts

Meet AZAdvances Intern Katie Nguyen

Meet AZAdvances Intern Katie Nguyen

My learning expectations were to research and learn about various clinical trials for glioblastomas, breast cancer, and lung cancers and to gain insight into the market landscape for drug development. I built a project that can be used as a reference for hundreds of...

0 Comments